Launch of Dual Energy Ablation Platform by Johnson & Johnson
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Yahoo Finance
- Product Innovation: The Dual Energy THERMOCOOL SMARTTOUCH SF Platform has been launched in Europe, integrating pulsed field and radiofrequency energy to provide personalized treatment options for cardiac ablation, enhancing physician flexibility and safety in procedures.
- Clinical Validation: Data from the SmartfIRE first-in-human study showed an 86.9% effectiveness rate among patients adhering to recommended workflows and PF/RF Index guidance, indicating the platform's potential to improve quality of life and reduce cardiovascular hospitalizations.
- Technology Integration: The platform leverages CARTO integration to deliver ultra-high-density mapping, catheter visualization, and contact-force feedback, enhancing procedural control and ensuring reproducible lesion creation tailored to diverse patient anatomies and clinical needs.
- Market Commitment: Johnson & Johnson's ongoing investment in the electrophysiology sector reflects its commitment to providing a broad range of treatment options, addressing the complex needs of conditions like atrial fibrillation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 239.080
Low
190.00
Averages
218.50
High
240.00
Current: 239.080
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Launch of Dual Energy Ablation Platform by Johnson & Johnson
- Product Innovation: The Dual Energy THERMOCOOL SMARTTOUCH SF Platform has been launched in Europe, integrating pulsed field and radiofrequency energy to provide personalized treatment options for cardiac ablation, enhancing physician flexibility and safety in procedures.
- Clinical Validation: Data from the SmartfIRE first-in-human study showed an 86.9% effectiveness rate among patients adhering to recommended workflows and PF/RF Index guidance, indicating the platform's potential to improve quality of life and reduce cardiovascular hospitalizations.
- Technology Integration: The platform leverages CARTO integration to deliver ultra-high-density mapping, catheter visualization, and contact-force feedback, enhancing procedural control and ensuring reproducible lesion creation tailored to diverse patient anatomies and clinical needs.
- Market Commitment: Johnson & Johnson's ongoing investment in the electrophysiology sector reflects its commitment to providing a broad range of treatment options, addressing the complex needs of conditions like atrial fibrillation.
See More
Coca-Cola and Johnson & Johnson: Reliable Dividend Investment Choices
- Coca-Cola's Market Position: Coca-Cola holds a significant position in the global beverage market with a market cap of $347 billion, and its strong brand influence and 61.82% gross margin enable it to consistently provide stable returns for investors, particularly highlighted by its 64 consecutive years of dividend increases, showcasing resilience during economic fluctuations.
- Johnson & Johnson's Diversified Portfolio: As one of the largest healthcare companies globally, Johnson & Johnson boasts a market cap of $580 billion and is projected to exceed $100 billion in sales this year, leveraging patent protections in pharmaceuticals and medical devices to ensure stable income even in economic downturns.
- Dividend Yield Comparison: Coca-Cola offers a dividend yield of 2.58%, surpassing the S&P 500's average of 1.1%, while Johnson & Johnson's yield stands at 2.17%, making both companies excellent choices for long-term investors, especially in uncertain market conditions.
- Future Growth Potential: Johnson & Johnson is launching several key products, including the robotic-assisted surgery device Ottava, expected to drive future revenue growth, while Coca-Cola continues to innovate its beverage portfolio to adapt to market demands, ensuring its long-term competitive advantage.
See More
Coca-Cola and Johnson & Johnson: Dividend Kings
- Dividend Growth Record: Both Coca-Cola and Johnson & Johnson have increased their dividends for 64 consecutive years, demonstrating strong financial stability and commitment to shareholders, which attracts many income-seeking investors.
- Market Leadership: Coca-Cola maintains consistent revenue and cash flow in the competitive consumer goods market due to its globally recognized brand and extensive product portfolio, and it is expected to continue delivering solid returns in the future.
- Innovation and Adaptability: Johnson & Johnson's diversified product portfolio in pharmaceuticals and medical devices allows it to sustain sales growth even during economic downturns, with projected sales exceeding $100 billion in 2023, further solidifying its market position.
- Future Growth Potential: Johnson & Johnson is launching several key products, including the robotic-assisted surgery device Ottava, which are expected to become future growth drivers, enhancing the company's long-term profitability.
See More
Stocks Rebound as Falling Oil Prices Boost Market Sentiment
- Market Rebound: Stocks climbed on Wednesday as the S&P 500 and Nasdaq Composite rebounded from two consecutive days of declines, primarily driven by falling oil prices, with West Texas Intermediate crude dropping below $70 a barrel for the first time since March, indicating improved market sentiment.
- Impact of Energy Prices: The decline in energy prices led to lower Treasury yields, benefiting interest rate-sensitive sectors such as housing and home improvement, with Home Depot shares advancing over 5%, reflecting increased investor confidence in these sectors.
- Nike CFO Transition: Nike announced that David Denton, a former executive at Lowe's and Pfizer, will succeed Matthew Friend as CFO effective August 17, and although shares fell nearly 2% on Wednesday, analysts believe this change will have limited impact on future performance, with the upcoming earnings report being closely watched for potential guidance adjustments.
- Alphabet Replaces Verizon: Alphabet will replace Verizon in the Dow Jones Industrial Average starting Monday, and while the stock rose 1.7% on the announcement, analyst Jeff cautioned against viewing this index addition as a major catalyst, emphasizing that it is largely symbolic and recognizes Alphabet's significance in the broader economy.
See More
Alphabet Joins Dow Industrials, Replacing Verizon
- Dow Component Change: Alphabet (GOOGL) replaces Verizon (VZ) in the Dow Industrials, marking a significant shift towards mega-cap tech within the 130-year-old index, which may alter investor perceptions of traditional sectors amidst a tech-dominated market.
- Performance Comparison: While the Dow still features strong traditional stocks like Caterpillar (CAT) and Cisco (CSCO), which are up nearly 75% and 60% respectively, Alphabet's inclusion could shift focus towards tech stocks, reflecting current market dynamics.
- Investor Sentiment Shift: Changes in Dow components often signal market trends, and Alphabet's addition may be interpreted as a sign that its market cap has become too significant to overlook, prompting investors to monitor its price action around previous breakout levels.
- Key Future Trajectory: Should Alphabet maintain its stock price above its old breakout zone, it could attract further buying support; conversely, a decline could render the Dow more aligned with Nasdaq characteristics, impacting overall market sentiment.
See More
Investors Shift to Steady Dividend Stocks Amid AI Rally Decline
- Investor Strategy Shift: As the rally in AI chip stocks wanes, investors are rotating out of high-volatility semiconductor stocks into steadier dividend-paying stocks, reflecting a reassessment of market risks amid economic uncertainty.
- Strong Dividend Stock Performance: By the close of trading, Johnson & Johnson (JNJ), Altria (MO), and Verizon (VZ) all saw share price gains of at least 3%, indicating a growing preference for these blue-chip stocks as safe havens in turbulent markets.
- Altria's Growth Potential: Despite declining smoking rates, Altria is maintaining profitability through consistent price increases and cost reductions, while new smoke-free products like oral nicotine pouches are providing fresh growth avenues, with a dividend yield nearing 6%.
- Verizon's Market Strategy: Verizon aims to eliminate customer pain points with simplified wireless and home internet plans, expecting to gain up to 1 million new retail postpaid phone subscribers by 2026, and its shares are trading at less than 10 times projected earnings, indicating strong investment potential.
See More
Launch of Dual Energy Ablation Platform by Johnson & Johnson
- Product Innovation: The Dual Energy THERMOCOOL SMARTTOUCH SF Platform has been launched in Europe, integrating pulsed field and radiofrequency energy to provide personalized treatment options for cardiac ablation, enhancing physician flexibility and safety in procedures.
- Clinical Validation: Data from the SmartfIRE first-in-human study showed an 86.9% effectiveness rate among patients adhering to recommended workflows and PF/RF Index guidance, indicating the platform's potential to improve quality of life and reduce cardiovascular hospitalizations.
- Technology Integration: The platform leverages CARTO integration to deliver ultra-high-density mapping, catheter visualization, and contact-force feedback, enhancing procedural control and ensuring reproducible lesion creation tailored to diverse patient anatomies and clinical needs.
- Market Commitment: Johnson & Johnson's ongoing investment in the electrophysiology sector reflects its commitment to providing a broad range of treatment options, addressing the complex needs of conditions like atrial fibrillation.
See More
Coca-Cola and Johnson & Johnson: Reliable Dividend Investment Choices
- Coca-Cola's Market Position: Coca-Cola holds a significant position in the global beverage market with a market cap of $347 billion, and its strong brand influence and 61.82% gross margin enable it to consistently provide stable returns for investors, particularly highlighted by its 64 consecutive years of dividend increases, showcasing resilience during economic fluctuations.
- Johnson & Johnson's Diversified Portfolio: As one of the largest healthcare companies globally, Johnson & Johnson boasts a market cap of $580 billion and is projected to exceed $100 billion in sales this year, leveraging patent protections in pharmaceuticals and medical devices to ensure stable income even in economic downturns.
- Dividend Yield Comparison: Coca-Cola offers a dividend yield of 2.58%, surpassing the S&P 500's average of 1.1%, while Johnson & Johnson's yield stands at 2.17%, making both companies excellent choices for long-term investors, especially in uncertain market conditions.
- Future Growth Potential: Johnson & Johnson is launching several key products, including the robotic-assisted surgery device Ottava, expected to drive future revenue growth, while Coca-Cola continues to innovate its beverage portfolio to adapt to market demands, ensuring its long-term competitive advantage.
See More
Coca-Cola and Johnson & Johnson: Dividend Kings
- Dividend Growth Record: Both Coca-Cola and Johnson & Johnson have increased their dividends for 64 consecutive years, demonstrating strong financial stability and commitment to shareholders, which attracts many income-seeking investors.
- Market Leadership: Coca-Cola maintains consistent revenue and cash flow in the competitive consumer goods market due to its globally recognized brand and extensive product portfolio, and it is expected to continue delivering solid returns in the future.
- Innovation and Adaptability: Johnson & Johnson's diversified product portfolio in pharmaceuticals and medical devices allows it to sustain sales growth even during economic downturns, with projected sales exceeding $100 billion in 2023, further solidifying its market position.
- Future Growth Potential: Johnson & Johnson is launching several key products, including the robotic-assisted surgery device Ottava, which are expected to become future growth drivers, enhancing the company's long-term profitability.
See More
Stocks Rebound as Falling Oil Prices Boost Market Sentiment
- Market Rebound: Stocks climbed on Wednesday as the S&P 500 and Nasdaq Composite rebounded from two consecutive days of declines, primarily driven by falling oil prices, with West Texas Intermediate crude dropping below $70 a barrel for the first time since March, indicating improved market sentiment.
- Impact of Energy Prices: The decline in energy prices led to lower Treasury yields, benefiting interest rate-sensitive sectors such as housing and home improvement, with Home Depot shares advancing over 5%, reflecting increased investor confidence in these sectors.
- Nike CFO Transition: Nike announced that David Denton, a former executive at Lowe's and Pfizer, will succeed Matthew Friend as CFO effective August 17, and although shares fell nearly 2% on Wednesday, analysts believe this change will have limited impact on future performance, with the upcoming earnings report being closely watched for potential guidance adjustments.
- Alphabet Replaces Verizon: Alphabet will replace Verizon in the Dow Jones Industrial Average starting Monday, and while the stock rose 1.7% on the announcement, analyst Jeff cautioned against viewing this index addition as a major catalyst, emphasizing that it is largely symbolic and recognizes Alphabet's significance in the broader economy.
See More
Alphabet Joins Dow Industrials, Replacing Verizon
- Dow Component Change: Alphabet (GOOGL) replaces Verizon (VZ) in the Dow Industrials, marking a significant shift towards mega-cap tech within the 130-year-old index, which may alter investor perceptions of traditional sectors amidst a tech-dominated market.
- Performance Comparison: While the Dow still features strong traditional stocks like Caterpillar (CAT) and Cisco (CSCO), which are up nearly 75% and 60% respectively, Alphabet's inclusion could shift focus towards tech stocks, reflecting current market dynamics.
- Investor Sentiment Shift: Changes in Dow components often signal market trends, and Alphabet's addition may be interpreted as a sign that its market cap has become too significant to overlook, prompting investors to monitor its price action around previous breakout levels.
- Key Future Trajectory: Should Alphabet maintain its stock price above its old breakout zone, it could attract further buying support; conversely, a decline could render the Dow more aligned with Nasdaq characteristics, impacting overall market sentiment.
See More
Investors Shift to Steady Dividend Stocks Amid AI Rally Decline
- Investor Strategy Shift: As the rally in AI chip stocks wanes, investors are rotating out of high-volatility semiconductor stocks into steadier dividend-paying stocks, reflecting a reassessment of market risks amid economic uncertainty.
- Strong Dividend Stock Performance: By the close of trading, Johnson & Johnson (JNJ), Altria (MO), and Verizon (VZ) all saw share price gains of at least 3%, indicating a growing preference for these blue-chip stocks as safe havens in turbulent markets.
- Altria's Growth Potential: Despite declining smoking rates, Altria is maintaining profitability through consistent price increases and cost reductions, while new smoke-free products like oral nicotine pouches are providing fresh growth avenues, with a dividend yield nearing 6%.
- Verizon's Market Strategy: Verizon aims to eliminate customer pain points with simplified wireless and home internet plans, expecting to gain up to 1 million new retail postpaid phone subscribers by 2026, and its shares are trading at less than 10 times projected earnings, indicating strong investment potential.
See More
